Hunter Biden blames dad's disastrous Trump debate on Ambien. What is it?
During a more than three-hour interview on the YouTube show Channel 5 with Andrew Callaghan that aired on July 21, Hunter Biden said his dad was experiencing effects from the prescription sleep aid while debating now-president Trump.
"I know exactly what happened in that debate," Hunter Biden said in a three hour-plus interview on the YouTube show Channel 5 with Andrew Callaghan that aired July 21. "He flew around the world ‒ basically the mileage that he could have flown around the world three times. He's 81 years old. He's tired as s--t. They give him Ambien to be able to sleep. He gets up on the stage, and he looks like he's a deer in the headlights, and it feeds into every f---ing story that anybody wants to tell."
Biden isn't the only public figure to blame regrettable behavior on Ambien. Years ago, Sen. Robert F. Kennedy's daughter Kerry Kennedy blamed Ambien for a drugged-driving incident, for which she was acquitted in 2014. In 2018, comedian Roseanne Barr said she was "Ambien tweeting" when a racist tweet of hers about Obama White House aide Valerie Jarrett led to the cancelation of her ABC sitcom.
But what exactly is Ambien − and how does it affect the human body? Here's what to know about the prescription sleep aide.
What is Ambien?
Ambien, also known by its generic name, zolpidem, is a prescription medication used to treat insomnia by helping individuals fall asleep quicker and stay asleep.
The Food and Drug Administration has expressed concern over how Ambien can impair activities, such as driving, especially into the morning hours. "Patients with high levels of zolpidem can be impaired even if they feel fully awake," the FDA wrote in a fact sheet about the medication.
A year ago: The Biden-Trump debate rematch that changed the election
Joe Biden, now 82, and his former White House aides have previously blamed the president's busy schedule for his poor debate performance on June 27, 2024, but have not publicly mentioned Ambien. A representative for the former president did not respond to a request from USA TODAY about Hunter Biden's remarks about the sleeping drug.
What are the side effects of Ambien?
Ambien's side effects include nausea, vomiting, muscle cramps and diarrhea.
The medication can also cause abnormal thinking and changes in behavior: "Some of these changes may be characterized by decreased inhibition ... similar to effects produced by alcohol," the FDA-approved labeling says.
Confusion and aggressiveness are also listed side effects. "Visual and auditory hallucinations have been reported as well as behavioral changes such as bizarre behavior, agitation and depersonalization," the label adds.
Previously: Hunter Biden says Joe Biden was taking Ambien before disastrous debate against Trump
The label also warns against a possible worsening of depression or suicidal thinking. Impairments to alertness, motor coordination and vision have also been reported.
Complex sleep behaviors, during which a person engaged in activities while not fully away, such as sleepwalking, sleep-driving and sleep-cooking, have also been associated with Ambien, the American Addiction Centers reports.
Additionally, the drug has been linked to amnesia.
What have others said about Ambien?
After Barr's comment about "Ambien tweeting," Sanofi, a pharmaceutical company that makes Ambien, tweeted in response: "While all pharmaceutical treatments have side effects, racism is not a known side effect of any Sanofi medication." Ambien was also one of the drugs found in Tiger Woods' system after police found him asleep in his car in the middle of a highway.
Other Ambien users have reported a variety of side effects, including sleepwalking, binge eating and even driving at night without realizing or remembering the incidents.
Ambien maker to Roseanne: Racism is not a side effect of our drug
Janet Makinen, one of the lead plaintiffs in a 2006 class-action lawsuit against Ambien maker Sanofi-Aventis' U.S. division, alleged she 'ate hundreds of calories of food, including raw eggs, uncooked yellow rice, cans of vegetables, loaves of bread, bags of chips and bags of candy' while on the medication, according to an amended complaint in the lawsuit filed in the Southern District of New York.
The lawsuit also alleged that fellow plaintiff Christina Brothers, a financial analyst, remembers taking Ambien one night in May 2005 and waking up 'on the concrete floor of a jail cell.'
The parties agreed to a stipulated dismissal in 2007 because differences in factual issues and the women's injuries made it impossible for the case to be certified as a class-action lawsuit on behalf of other Ambien users.
Contributing: Joey Garrison and Ashley May
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Trump's Next Job: Selling Skeptical Americans on His Economy
(Bloomberg) -- Six months into his comeback term, Donald Trump has taken full ownership of the US economy. For better or worse, his party must now sell it to voters. We Should All Be Biking Along the Beach Seeking Relief From Heat and Smog, Cities Follow the Wind Chicago Curbs Hiring, Travel to Tackle $1 Billion Budget Hole NYC Mayor Adams Gives Bally's Bronx Casino Plan a Second Chance Boston's Dumpsters Overflow as Trash-Strike Summer Drags On The president has hailed the world's 'hottest' economy – and found others to blame for any wobbles. When Friday's jobs report showed a dramatic slowdown in hiring, he fired the head of the agency that published it. He's pinned some frustrations on his predecessor Joe Biden, and continues to berate the Federal Reserve for what he considers too-high interest rates. But for political purposes, his takeover has now been cemented — after passage of the 'One Big Beautiful Bill' tax-and-spending law, and the latest phase of his global tariff rollout. Commerce Secretary Howard Lutnick trumpeted the transition: 'The Trump Economy has officially arrived,' he posted on social media. The question is whether Americans like it. Next year Trump's economic record will be on the midterm ballot. Polls suggest voters are unhappy with the tariffs and tax plans — potentially giving Democrats an opening. The loss of GOP majorities in Congress could stall Trump's legislative agenda and expose him to impeachment efforts, as it did in his first term. The July employment figures, with job creation running at the weakest pace since the pandemic, were the latest indicator of a slowing economy. GDP shrank in the first quarter then rebounded in the second, as trade shifts skewed the numbers — but the overall pace in the first half of 2025 has been around half of last year's, with consumers hitting the brakes amid trade-war uncertainty. Still, unemployment remains low and so far there's been little sign of the tariff-led surge in prices that many pundits warn of. 'The economy has held up remarkably well. Inflation has stayed relatively tame. But I do think there are storm clouds on the horizon,' said Republican strategist Marc Short, who served in Trump's first administration. Many businesses have so far avoided passing on tariff costs to consumers, he said, but 'the frog has been boiling all along.' Trump announced another round of tariff hikes this week, after months of often chaotic threats and reversals. Almost all US trading partners now face higher rates. The import taxes are bringing in billions in government revenue, but the longer-term economic impact remains unclear. Critics say US consumers and businesses will foot the bill. A recent Fox News poll shows that 62% of voters disapprove of Trump's handling of tariffs – while 58% are against the tax and spending bill, and 55% are unhappy with his overall handling of the economy. Voters are especially sensitive to the cost of living right now after prices skyrocketed under the Biden administration. Fed Chair Jerome Powell has cited the risk that tariffs could rekindle inflation as one reason for holding interest rates steady – to Trump's fury. The president has campaigned aggressively for lower rates, hinting he may fire Powell before his term ends next May. On Friday he called on the Fed's board to 'assume control' if Powell doesn't deliver a cut. There were some signs in June's price data that tariffs are starting to nudge prices higher for products like furniture and appliances. Still, the White House has a decent story to tell, according to Republican strategist Alex Conant. 'I would certainly take this economy over two or three years ago,' he said. 'There are two things that crush a president, inflation or unemployment. Right now both are low.' Democrats see opportunities to go after Trump on his tax-and-spending legislation as well as his tariffs. The measure includes new breaks for tips and overtime pay – but also steep cuts to health programs that will hurt many low-income Americans. 'Our summer's all about Cancel The Cuts,' former House Speaker Nancy Pelosi said on social media. 'I'll be looking at how House and Senate Republicans fare back home as they try to sell the recent budget bill,' said Democratic strategist Jim Manley. 'If you look at the polling, Democrats have to focus on his handling of the economy, because Americans are not happy.' With tariffs largely in place, the White House in August plans to start promoting its tax law. State and local officials were at the White House this week getting briefed on the legislation, one official said. Another White House insider said Trump was expected to hit the road as part of the effort. 'Naysayers and Doomsayers' Key parts of the bill like the tips exemption are 'huge immediate political winners,' Conant said. 'They should not only run on them, they should attack Democrats for opposing them.' The law also extends tax cuts from Trump's first term, which had been due to expire. That's potentially the GOP's strongest argument to voters — 'if they'd not done it, can you imagine what your tax bill would've been like next April' — according to veteran Republican pollster Frank Luntz. 'They should be saying it, they're doing it to some degree,' he told Bloomberg TV on Friday. 'But it's not being heard.' The White House maintains that the economy is booming. 'All the naysayers and the doomsayers have been proven wrong,' Communications Director Stephen Cheung said. And Trump is pulling other levers to improve GOP chances in the midterms. He's raised $236 million for his political operation in the first six months of 2025 — an unprecedented sum for a second-term president. The latest filings to the Federal Election Commission suggest most of that cash will be available for GOP House and Senate candidates. Trump is also urging Texas lawmakers to redraw the state's congressional map in an effort to win House districts that are more favorable to Republicans — a move Democrats have decried as a power grab. Midterm elections historically favor the party out of power — potentially giving a boost to Democrats, who were soundly beaten in 2024. But the opposition party is also struggling in the polls, and hasn't coalesced around an effective appeal to voters. Former Chicago Mayor Rahm Emanuel, who has said he is considering a 2028 Democratic presidential bid, said the party has a clear economic message available for the midterms – which includes focusing on tariffs as an effective tax hike. 'This is all about accepting that Donald Trump owns this economy,' Emanuel said. How Podcast-Obsessed Tech Investors Made a New Media Industry Everyone Loves to Hate Wind Power. Scotland Found a Way to Make It Pay Off Russia Builds a New Web Around Kremlin's Handpicked Super App Cage-Free Eggs Are Booming in the US, Despite Cost and Trump's Efforts What's Really Behind Those Rosy GDP Numbers? ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
41 minutes ago
- USA Today
Democrats have devolved into a clown show. No wonder polls show voters prefer GOP.
Are Democrats OK? They appear desperate and increasingly are becoming a clown show without direction or purpose. Forget a tale of two cities, the vast differences between today's two major political parties is far more relevant. A recent Wall Street Journal survey shows that the Democratic Party got its lowest rating from voters in 35 years. Despite President Donald Trump's tariffs, Republicans are still preferred on most issues. Who can blame voters? Under President Joe Biden, inflation hit a 40-year high, Russia invaded Ukraine, Hamas brutally attacked Israel and Iran built a robust nuclear program. Then Americans learned, while he was running for reelection, that Biden suffered from serious cognitive decline, raising questions about what the Democratic Party knew and when. Americans lost trust that Democrats were transparent and honest. Nine months after Trump was reelected, Democrats still lack direction and competent leaders. Here are a few examples: Are Democrats OK? They appear desperate, and increasingly are becoming a clown show without direction or purpose. Democratic Party's future looks grim The chaos and aimlessness at the national level also exists in Democratic-controlled states. In California and New York, progressive leaders ensure that residents are hurt by high tax rates and other policies that push businesses to relocate. Opinion: In-N-Out owner places order to go − out of California California and New York serve as cautionary tales for much of the country. As Democratic states lose population, Florida, Texas and other deep red states are growing rapidly. A Democrat hasn't won statewide office in Texas since 1994. And no Democrat currently holds statewide office in Florida. Developing new political talent in the second and third largest states in the nation − and in states like Indiana, Ohio and Tennessee − is now almost impossible for Democrats, a reality that is sure to hurt the party's future on the local, state and national levels. Reapportionment after the 2030 Census also is likely to be brutal for Democrats. The Brennan Center, a progressive think tank, reported that "California would lose 4 of its 52 congressional districts in reapportionment − only the second time the Golden State has ever lost representation. New York, meanwhile, would lose three seats, Illinois two, and Pennsylvania one, leaving all three states with congressional delegations half the size they were in 1940." It's not just House seats that Democratic states will shed. Red states also stand to gain more Electoral College votes, which gives future Republican presidential candidates a stronger mathematical advantage. GOP is humming now and into the future Meanwhile, Trump has accomplished more in his first six months than Joe Biden did in four years. Trump is overhauling the federal bureaucracy, reworking the global economy on more favorable terms for Americans, persuading American allies to pay more for their own defense, forcing universities to better protect Jewish students and faculty and to finally respect conservatives on campus, safeguarding women's rights, promoting the U.S. energy sector and other industries to a remarkable degree around the world, and pushing for peace from India to Ukraine. Opinion: Trump wins again – Columbia's $200 million fine will reshape higher education Trump also is building a conservative political dynasty that is set to take his place after he leaves office in 2029. Vice President JD Vance is the GOP's most promising star. He has proved to be articulate and passionate on difficult issues, in the U.S. and while representing America overseas. Intelligent and media savvy, Vance has most, if not all, of the positive qualities a leader needs with few of Trump's less savory qualities. Vance is the heavy early favorite to win the GOP presidential nomination in 2028 and could very well lead Republicans to political dominance for years to come. It's not only Vance, however, with a promising future. New York Republican Rep. Elise Stefanik has made a name for herself standing against antisemitism, especially in institutions of higher education. She's sharp, bold and outspoken about her values. At just 31 years old, Texas Rep. Brandon Gill made headlines when he questioned NPR CEO Katherine Maher in a hearing about her leftist political bias. Secretary of State Marco Rubio is strongly and effectively representing U.S. interests around the globe. Only 54, Rubio, a former senator and presidential candidate from Florida, is a potential Republican presidential nominee for the next two decades. The Republican Party is in a strong position now and could be even more dominant after Trump leaves office. Democrats, in contrast, look aimless now, and their future appears even more grim. No wonder voters aren't attracted to them. Nicole Russell is a columnist at USA TODAY and a mother of four who lives in Texas. Contact her at nrussell@ and follow her on X, formerly Twitter: @russell_nm. Sign up for her weekly newsletter, The Right Track, here.
Yahoo
2 hours ago
- Yahoo
Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). This open-label, multi-center international study plans to enroll 66 patients with proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mCRC to evaluate the safety and preliminary efficacy of the triplet therapy. Enrollment is planned in Taiwan and Australia. Tislelizumab, a PD-1 monoclonal antibody, used in this trial is provided by BeOne Medicines (formerly known as BeiGene). Further details on this collaboration were disclosed by Anbogen in a press release dated September 27, 2024. ABT-301 is an oral HDAC1/2/3 inhibitor. Preclinical studies have shown that it promotes CD8+ cytotoxic T cell infiltration and activity, enhances antigen presentation, and inhibits M-MDSCs cells, effectively modulating the tumor microenvironment and converting "cold tumors" into "hot tumors" to improve the efficacy of immune checkpoint inhibitors. ABT-301 also exhibits pro-apoptotic, anti-angiogenic, and tumor metabolic regulation effects. As a single-molecule, multi-modality anti-cancer agent, ABT-301 aims to enhance tumor treatment when combined with the two antibody drugs. Notably, in a previous Phase 1 monotherapy clinical trial involving 23 participants, ABT-301 did not exhibit neutropenia or cardiac toxicity, which are commonly observed in other HDAC inhibitors—further supporting its suitability for use in combination immunotherapy. Approximately 95% of mCRC patients are pMMR or non-MSI-H types—commonly referred to as "cold tumors"—which respond poorly to current immunotherapies. Only around 5% of patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) "hot tumors" typically benefit from immune checkpoint inhibitors. According to GlobalData, an estimated 370,000 new pMMR/non-MSI-H patients in second-line or later settings are diagnosed annually across the U.S., China, Japan, and the top five European markets (UK, France, Germany, Spain, and Italy), representing a potential market size of USD $9 billion. Anbogen stated that the FDA's IND approval marks a key milestone in the development of ABT-301, demonstrating the safety profile of the triplet therapy and advancing it into clinical stages. The company emphasized that the study targets the majority of patients (over 90%) with poor responses to immunotherapy, aiming to provide a novel treatment option and address this unmet clinical need. Looking ahead, Anbogen will continue to advance the clinical development of ABT-301 while pursuing global licensing and strategic partnerships to accelerate commercialization and market entry. The company is also launching its Series B fundraising to attract strategic partners committed to advancing innovative cancer therapies and global expansion. About Anbogen Therapeutics Anbogen Therapeutics is a clinical-stage biotechnology company committed to developing precision oncology therapies that improve the lives of cancer patients worldwide. The company currently has two core assets: ABT-301, a HDAC1/2/3 inhibitor with immune-modulating capabilities, enhances the tumor microenvironment and boosts immune responses. It significantly improves the efficacy of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC), offering a new treatment pathway for the majority of patients who do not benefit from ICIs. ABT-501 is a novel Peptide Drug Conjugate (PDC) that targets LHRH-receptor tumors using a proprietary delivery system. It has shown strong efficacy and safety in triple-negative breast cancer models, with potential for broader cancer applications. For more information, please visit Anbogen's official website at View original content: SOURCE Anbogen Therapeutics
